Masimo's Stork Baby-Monitoring System Gets FDA Approval
By Ben Glickman
Masimo's baby-monitoring system Stork has received approval from the U.S. Food and Drug Administration for medical uses.
The system is cleared by the FDA for prescription use in healthy and sick babies up to 18 months old.
Stork allows parents to monitor babies' oxygen saturation, pulse rate and skin temperature. Users can receive alarms regarding these metrics and can share information with doctors remotely.
The Irvine, Calif.-based medical-device company said Monday that the system was available at retailers nationwide as a non-medical device and could now be used as a medical device with a prescription.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 18, 2023 13:13 ET (18:13 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth